Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Descriptor ID |
D002295
|
MeSH Number(s) |
C04.557.470.200.430
|
Concept/Terms |
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in this website by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 8 | 1 | 9 |
1995 | 6 | 0 | 6 |
1996 | 9 | 0 | 9 |
1997 | 10 | 0 | 10 |
1998 | 8 | 1 | 9 |
1999 | 10 | 2 | 12 |
2000 | 9 | 0 | 9 |
2001 | 15 | 1 | 16 |
2002 | 9 | 0 | 9 |
2003 | 21 | 6 | 27 |
2004 | 11 | 3 | 14 |
2005 | 9 | 3 | 12 |
2006 | 28 | 4 | 32 |
2007 | 22 | 2 | 24 |
2008 | 20 | 4 | 24 |
2009 | 22 | 1 | 23 |
2010 | 28 | 2 | 30 |
2011 | 14 | 2 | 16 |
2012 | 18 | 1 | 19 |
2013 | 13 | 2 | 15 |
2014 | 19 | 0 | 19 |
2015 | 15 | 2 | 17 |
2016 | 17 | 1 | 18 |
2017 | 18 | 0 | 18 |
2018 | 17 | 0 | 17 |
2019 | 22 | 0 | 22 |
2020 | 17 | 1 | 18 |
2021 | 28 | 0 | 28 |
2022 | 24 | 0 | 24 |
2023 | 23 | 0 | 23 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Evolution of front-line immunotherapy for metastatic urothelial cancer. Lancet Oncol. 2024 Jan; 25(1):2-3.
-
Contemporary Issues in Urothelial Carcinoma of Upper Urinary Tract. Adv Anat Pathol. 2024 Mar 01; 31(2):80-87.
-
Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up. Future Oncol. 2024 Feb; 20(5):231-243.
-
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023 Nov 23; 389(21):1961-1971.
-
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol. 2024 Jan; 35(1):107-117.
-
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study. Urol Oncol. 2023 Dec; 41(12):486.e15-486.e23.
-
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 Dec 10; 41(35):5437-5447.
-
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. Eur Urol. 2024 Mar; 85(3):229-238.
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023 08; 24(8):925-935.
-
Poly (ADP-ribose) Polymerase Inhibition in Advanced Urothelial Carcinoma. JCO Precis Oncol. 2023 08; 7:e2300293.